No­var­tis vet Dan­ny Bar-Zo­har leaps back in­to R&D, tak­ing over the de­vel­op­ment team at Mer­ck KGaA as Lu­ciano Ros­set­ti steps out

Af­ter a brief stint as a biotech in­vestor at Syn­cona, No­var­tis vet Dan­ny Bar-Zo­har is back in R&D, and he’s tak­ing the lead po­si­tion at Mer­ck KGaA’s drug di­vi­sion.

Bar-Zo­har had led late-stage clin­i­cal de­vel­op­ment across a va­ri­ety of ar­eas — neu­ro­science, im­munol­o­gy, on­col­o­gy and oph­thal­mol­o­gy, among oth­ers — be­fore join­ing the mi­gra­tion of tal­ent out of the Basel-based multi­na­tion­al. He had been at No­var­tis for 7 years, which fol­lowed an ear­li­er chap­ter in re­search at Te­va.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER